Analysts expect Intellia Therapeutics Inc (NASDAQ:NTLA) to post $11.98 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Intellia Therapeutics’ earnings. The highest sales estimate is $18.50 million and the lowest is $7.00 million. Intellia Therapeutics posted sales of $6.67 million during the same quarter last year, which suggests a positive year over year growth rate of 79.6%. The company is expected to issue its next quarterly earnings results on Wednesday, March 13th.

According to Zacks, analysts expect that Intellia Therapeutics will report full-year sales of $34.51 million for the current year, with estimates ranging from $29.55 million to $41.05 million. For the next fiscal year, analysts expect that the firm will report sales of $42.95 million, with estimates ranging from $20.00 million to $95.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Intellia Therapeutics.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Wednesday, October 31st. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.05). The company had revenue of $7.41 million during the quarter, compared to analyst estimates of $11.58 million. Intellia Therapeutics had a negative return on equity of 31.70% and a negative net margin of 308.81%. The business’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.44) earnings per share.

NTLA has been the topic of several research analyst reports. Raymond James initiated coverage on shares of Intellia Therapeutics in a research report on Thursday, September 20th. They issued a “market perform” rating on the stock. BidaskClub upgraded shares of Intellia Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, September 15th. ValuEngine lowered shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, September 22nd. Zacks Investment Research lowered shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 7th. Finally, Chardan Capital restated a “buy” rating and issued a $57.50 price target on shares of Intellia Therapeutics in a research report on Friday, August 24th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $35.50.

NASDAQ NTLA traded down $0.56 during midday trading on Thursday, hitting $18.78. The company had a trading volume of 602,129 shares, compared to its average volume of 725,684. Intellia Therapeutics has a fifty-two week low of $16.33 and a fifty-two week high of $35.99.

Several large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc lifted its holdings in shares of Intellia Therapeutics by 75.4% during the 2nd quarter. Legal & General Group Plc now owns 5,427 shares of the company’s stock worth $149,000 after acquiring an additional 2,333 shares during the period. Great West Life Assurance Co. Can lifted its holdings in shares of Intellia Therapeutics by 2.5% during the 2nd quarter. Great West Life Assurance Co. Can now owns 97,031 shares of the company’s stock worth $2,652,000 after acquiring an additional 2,395 shares during the period. TRUE Private Wealth Advisors lifted its holdings in shares of Intellia Therapeutics by 23.5% during the 2nd quarter. TRUE Private Wealth Advisors now owns 13,296 shares of the company’s stock worth $363,000 after acquiring an additional 2,533 shares during the period. Macquarie Group Ltd. bought a new position in shares of Intellia Therapeutics during the 2nd quarter worth about $101,000. Finally, Patriot Financial Group Insurance Agency LLC bought a new position in shares of Intellia Therapeutics during the 3rd quarter worth about $116,000. 66.59% of the stock is owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Featured Article: What factors cause inflation to rise?

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.